Minerva Neurosciences Inc. Stock
The price for the Minerva Neurosciences Inc. stock decreased slightly today. Compared to yesterday there is a change of -€0.020 (-0.920%).
For the coming years our community has positive and negative things to say abot the Minerva Neurosciences Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Expected dividend yield" there were negative voices in the community.
Minerva Neurosciences (NASDAQ: NERV) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients suffering from neuropsychiatric disorders. With a primary emphasis on central nervous system diseases such as schizophrenia, major depressive disorder, insomnia, and Parkinson's, Minerva Neurosciences is committed to addressing unmet medical needs and advancing the understanding of the underlying biology of these conditions. Utilizing a strong research and development platform, the company aims to create a diversified portfolio of novel therapies that have the potential to significantly improve patients' quality of life and help them lead more fulfilling lives.
Pros and Cons of Minerva Neurosciences Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Minerva Neurosciences Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Minerva Neurosciences Inc. | -0.920% | 6.195% | 6.195% | -57.219% | -58.869% | -87.685% | - |
| Evolus Inc | - | 0.000% | 7.477% | 37.725% | 27.072% | 32.948% | - |
| Ardelyx Inc. | 3.070% | 1.608% | 5.441% | 102.500% | 9.308% | 7.085% | - |
| Salarius Pharmaceuticals Inc. | - | -3.015% | -6.311% | -66.724% | -30.450% | -98.501% | -99.994% |
Comments
Minerva Neurosciences, Inc. (NASDAQ: NERV) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for NERV provided by MarketBeat
Minerva Neurosciences, Inc. (NASDAQ: NERV) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for NERV provided by MarketBeat
Minerva Neurosciences, Inc. (NASDAQ: NERV) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Show more
Ratings data for NERV provided by MarketBeat